Kane BiotechKNBIF -4.79% EV-to-EBITDA is -3.68 as of Jul. 02, 2026. The stock has 6 warning signs investors should review. Among 396 Biotechnology companies, Kane Biotech ranks worse than 252525% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kane Biotech's enterprise value is $5.20 Mil.
Kane Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.41 Mil. Therefore, Kane Biotech's EV-to-EBITDA for today is -3.68.
The historical rank and industry rank for Kane Biotech's EV-to-EBITDA or its related term are showing as below:
KNBIF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -47.76 Med: -4.48 Max: -0.91
Current: -3.68
During the past 13 years, the highest EV-to-EBITDA of Kane Biotech was -0.91. The lowest was -47.76. And the median was -4.48.
KNBIF's EV-to-EBITDA is ranked worse than 100% of 396
companies
in the Biotechnology industry
Industry Median: 13.045
vs KNBIF: -3.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Kane Biotech (OTCPK:KNBIF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kane Biotech's PE Ratio (TTM) for today is calculated as:
Kane Biotech's share price for today is $0.0195.
Kane Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Kane Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNBIF vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Kane Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kane Biotech's EV-to-EBITDA falls into.
Kane Biotech's current Enterprise Value is $5.20 Mil.
Kane Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kane Biotech (KNBIF) has a EV-to-EBITDA of -3.68 as of Jul. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kane Biotech. According to the industry distribution chart, Kane Biotech ranks #999999 out of 396 companies in the Biotechnology industry.
Is Kane Biotech's EV-to-EBITDA too high?
Kane Biotech's current EV-to-EBITDA is -3.68. Based on the distribution chart, Kane Biotech ranks #999999 out of 396 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Kane Biotech's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #999999 out of 396 companies for EV-to-EBITDA. This places Kane Biotech in the lower half of its industry. The industry median EV-to-EBITDA is 13.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.05, based on 396 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kane Biotech. For the Biotechnology industry, the median EV-to-EBITDA is 13.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kane Biotech's current EV-to-EBITDA is -3.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current EV-to-EBITDA of -3.68. The current EV-to-EBITDA is -3.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current EV-to-EBITDA is -3.68 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 